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Background: The CC-chemokine receptor 4 (CCR4) is thought potentially to play a critical role in asthma
pathogenesis due to its ability to recruit type 2 T-helper lymphocytes to the inflamed airways. Therefore, CCR4
provides an excellent target for anti-inflammatory therapy.
Methods: The safety, tolerability, pharmacokinetics and pharmacodynamics of the CCR4 antagonist GSK2239633,
N-(3-((3-(5-chlorothiophene-2-sulfonamido)-4-methoxy-1H-indazol-1-yl)methyl)benzyl)-2-hydroxy-2-
methylpropanamide, were examined in healthy males. Two studies were performed: 1) an open-label, study in
which six subjects received a single intravenous infusion of [14C]-GSK2239633 100 μg (10 kBq) (NCT01086462), and
2) a randomised, double-blind, placebo-controlled, cross-over, ascending dose study in which 24 subjects received
single oral doses of GSK2239633 150–1500 mg (NCT01371812).
Results: Following intravenous dosing, plasma GSK2239633 displayed rapid, bi-phasic distribution and slow terminal
elimination (t½: 13.5 hours), suggesting that GSK2239633 was a low to moderate clearance drug. Following oral
dosing, blood levels of GSK2239633 reached Cmax rapidly (median tmax: 1.0–1.5 hours). Estimated GSK2239633
bioavailability was low with a maximum value determined of only 16%. Food increased GSK2239633 systemic
exposure (as assessed by AUC and Cmax). Increases in AUC and Cmax were less than dose proportional. Adverse
events were reported by three subjects (50%) following intravenous administration, and by 19 subjects (79%)
following oral administration; most (46/47; 98%) events were mild/moderate in intensity. GSK2239633 1500 mg
inhibited thymus- and activation-regulated chemokine-induced (TARC) actin polymerisation reaching a mean CCR4
occupancy of 74%.
Conclusion: In conclusion, GSK2239633 was well-tolerated and capable of inhibiting TARC from activating the
CCR4 receptor.
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Allergic asthma is characterised by chronic inflammation
of the airways, commonly triggered by environmental
aeroallergens. This inflammatory process in asthma is
characterised by inflammatory cell recruitment, increased
mucus production, periodic airway smooth muscle con-
traction and vascular vasodilation [1-4]. Subsequently,
Type 2 T helper (Th2) lymphocytes, and other cell types,
are recruited from peripheral blood into the inflamed
tissue where they produce cytokines that induce eosino-
phil recruitment, stimulate the production of allergen-
specific immunoglobulin E by B-cells and increase the
permeability of the endothelium to allow further recruit-
ment of inflammatory cells [5-7].
One mode of Th2 lymphocyte recruitment to inflamed
airways [8-11] is through the specific binding of the che-
mokines thymus- and activation-regulated chemokine
(TARC) and monocyte-derived chemokine (MDC) to
the CC-chemokine receptor 4 (CCR4) expressed on the
surface of a subset of Th2 cells [12-17]. High levels of
TARC and MDC have been detected in the lungs of
patients with asthma following an allergen challenge
[18,19], and high numbers of Th2 cells recovered in
bronchial biopsies from patients with asthma have been
found to be CCR4 positive [20-22]. As chemokine recep-
tors play a key role in inflammatory processes, they pro-
vide excellent targets for anti-inflammatory therapy
[23-26]. The targeting of CCR4 is believed to be a safe
strategy as initial clinical studies with mogamulizumab, a
humanised anti-CCR4 monoclonal antibody, have given
no indication of an increase in the number of infections
or any degree of immunosuppression related to moga-
mulizumab [27]. Further, there was no evidence of any
CCR4-specific adverse clinical effects in patients with
T-cell lymphomas treated with mogamulizumab [27].
GSK2239633 N-(3-((3-(5-chlorothiophene-2-sulfonamido)-
4-methoxy-1H-indazol-1-yl)methyl)benzyl)-2-hydroxy-
2-methylpropanamide, compound 7r in [28], is an
allosteric antagonist of human CCR4 [29]. In vitro,
GSK2239633 inhibited the binding of [125I]-TARC to hu-
man CCR4 with a pIC50 of 7.96 ± 0.11 and also inhibited
TARC-induced increases in the F-actin content of isolated
human CD4+ CCR4+ T-cells with a pA2 of 7.11 ± 0.29
[unpublished observations]. Conflicting pharmacokinetic
profiles for GSK2239633 were obtained in the rat and
dog, leading to variable predictions of the human pharma-
cokinetic profile. Therefore, before oral GSK2239633 was
administered to humans for the first time, a Microdose
Intravenous Study using a radio-labelled dose [30] of
GSK2239633 was conducted in healthy subjects. This
Microdose Intravenous Study revealed that plasma clear-
ance of GSK2239633 was low to moderate or approxi-
mately 40% of liver blood flow when plasma clearance was
converted to blood clearance. To obtain information at apotentially clinically relevant dose level, a study using sin-
gle ascending oral doses of GSK2239633 was conducted
in healthy subjects. Here we report the results obtained in
both of these clinical studies.
Methods
Study population
All subjects provided signed and dated informed consent
prior to screening. Local Ethics Review Committees pro-
vided approval for both studies (Microdose Intravenous
Study: Independent Ethics Committee of the Foundation
“Evaluation of the Ethics of Biomedical Research”, Assen,
The Netherlands; Single Oral Dose Study: Medische
Ethische ToetsingsCommissie, Stichting Beoordeling Ethik
Biomedisch Onderzoek, Assen, The Netherlands) and they
were conducted in accordance with Good Clinical Practice
and the guiding principles of the 2008 Declaration of
Helsinki [31].
Microdose intravenous study
Healthy subjects aged 18–50 years with a body mass index
of 18.5–29.9 kg/m2 were eligible. Subjects had to be non-
smokers or ex-smokers for a minimum of 6 months prior
to screening and with a smoking history of <5 pack years.
Exclusion criteria included positive testing for hepatitis B
surface antigen, hepatitis C antibody and human immuno-
deficiency virus. Subjects unwilling to abstain from red
wine, Seville oranges, grapefruit or grapefruit products
7 days prior to dosing were also ineligible.
Single oral dose study
Healthy subjects aged 18–65 years with a body mass
index of 18.5–29.9 kg/m2 and a smoking history as des-
cribed for the Microdose Intravenous Study were eligi-




This was an open-label, single-dose study conducted from
21 January 2010 to 18 February 2010 at PRA International,
Zuidlaren, The Netherlands (GlaxoSmithKline protocol:
CC4114041; Clinicaltrials.gov identifier: NCT01086462).
Subjects received a single intravenous infusion of approxi-
mately 10 kBq [14C]-GSK2239633 100 μg over 15 minutes.
Subjects attended a screening visit within 30 days prior to
receiving the first dose of study medication. Subjects were
admitted to the clinical unit on Day −1 and remained there
until 48 hours post-dose. As this was the first time
GSK2239633 100 μg had been administered to humans,
dosing was staggered so that only one subject received the
study medication on Day 1. As the study medication was
well-tolerated, the remaining subjects were dosed the fol-
lowing day in a staggered dosing schedule (20-minute
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a follow-up telephone call 4–10 days after the last dose of
study medication.Single oral dose study
This was a randomised, double-blind, placebo-controlled,
cross-over, single ascending-dose study conducted from
29 March 2011 to 1 July 2011 at PRA International,
Zuidlaren, the Netherlands (GlaxoSmithKline protocol:
CC4114660; Clinicaltrials.gov identifier: NCT01371812).
Subjects completed a screening visit within 28 days prior
to receiving the first dose of study medication. Subjects
were admitted to the clinical unit the day before each
dosing session for baseline assessments that included a
physical examination and clinical laboratory tests. Single
ascending oral doses of GSK2239633 or placebo were
administered to two interlocking and alternating cohorts
(Additional file 1: Figure S1) (Cohort 1 and Cohort 2),
each of which consisted of 12 male subjects randomised
to receive either active or placebo (eight active: four
placebo). The randomisation schedule was generated
prior to the start of the study using validated internal
software. Subjects from Cohort 1 underwent four
dosing sessions; the starting dose of GSK2239633 was
150 mg, followed by 600 mg, 1200 mg and 1200 mg
after eating the standard United States Food and Drug
Administration (FDA) high fat/high caloric meal to
assess any food effect. Subjects from Cohort 2 under-
went three dosing sessions; the starting dose of
GSK2239633 was 300 mg, followed by 900 mg and
1500 mg. As this was a first-time-in-human study, do-
sing was staggered over 2 days so that on Day 1 one
subject received GSK2239633 and one subject received
placebo at each dosing session in both cohorts (with
the exception of the food effect dosing session for
Cohort 1). On Day 2, the remaining subjects were
dosed provided GSK2239633 was well-tolerated on Day 1.
Subjects fasted for 10 hours before each dosing ses-
sion, except those in last period of Cohort 1 who ate
30 minutes prior to administration of GSK2239633
1200 mg. For both cohorts, no food was permitted up
to 4 hours after administration of study medication.
During a 2-hour period (1 hour pre-dose until 1 hour
post-dose), no water was allowed with the exception of
that taken with the study medication (240–300 mL).
After receiving randomised treatment, subjects underwent
a period of observation and assessments for 3 days.
They returned to the clinical unit, following a washout
period of approximately 14 days, to receive their next
randomised dose of study medication, with additional
3-day inpatient assessments. Subjects returned for a
follow-up visit 10–14 days after their last dose of study
medication.Dosing and sample collection
Microdose intravenous study
Subjects were dosed over 15 minutes with: 10 μg/mL
GSK2239633 (14C-labelled) in a saline solution for infu-
sion (0.9% w/v sodium chloride solution) containing
10% w/v (2-hydroxypropyl)-beta-cyclodextrin.
Blood samples for pharmacokinetic analysis of plasma
total radioactivity and GSK2239633 were collected at
screening, Day −1, pre-dose and at 5, 10, 15, 20, 30, 45
minutes and 1, 1.5, 1.75, 2.25, 3.25, 4.25, 6.25, 8.25,
12.25, 16.25, 18.25, 24.25, 30.25, 36.25 and 48.25 hours
from start of the infusion. Urine samples were collected
prior to dosing and then until 24 hours after the infusion
ended.
Single oral dose study
Subjects were dosed with GSK2239633 as a capsule for-
mulation (Swedish orange coloured opaque hard gelatin
capsules) with a unit dosage strength of 150 mg. Sub-
jects received between one and 10 capsules (depending
on the dose level), which were swallowed with 240 mL
of water (or up to 300 mL of water in total for the
higher number of capsules). Subjects randomised to pla-
cebo in each dosing session received the same number
of capsules as those randomised to active treatment for
the same dosing session.
Blood samples were drawn for pharmacokinetic analy-
sis pre-dose and at 5, 15 and 30 minutes and 1, 2, 3, 4,
8, 10, 24 and 48 hours post-dose. For pharmacodynamic
analysis, blood was collected pre-dose and at 1, 4 and
24 hours post-dose. The pharmacodynamic analysis was
only conducted for subjects in the fasted condition; no
analysis was performed for the fed cohort. An aliquot of
urine was collected pre-dose; after dosing, all urine was
collected and pooled during a 24-hour interval.
Pharmacokinetic analysis
Microdose intravenous study
The primary endpoints were maximum observed con-
centration (Cmax), area under the concentration-time
curve from time 0 to last measurable concentration
(AUC0–t), AUC from time 0 extrapolated to infinity
(AUC0–∞) and terminal half-life (t½) of GSK2239633 and
[14C]-radioactivity, apparent clearance (CL) and volume
of distribution at steady state (Vss) of GSK2239633 and
cumulative urinary excretion of total radioactivity for 24
hours post-dose. Total radioactivity was measured directly
by accelerator mass spectrometry. Plasma GSK2239633
concentrations were determined using an internally vali-
dated analytical method by accelerator mass spectrometry
(further details provided as Additional file 1 material).
Urine radioactivity levels were measured by liquid
scintillation counting with an external standardisation
method. The lower limit of quantification (LLQ) was
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equiv/mL for the total plasma radioactivity assay. The
LLQ for GSK2239633 in urine was 5 μg GSK2239633
equiv. Pharmacokinetic parameters for each subject were
derived from plasma GSK2239633 concentration-time
profiles by non-compartmental analysis using Win-
Nonlin Professional Edition Version 5.2 or above (Phar-
sight Corporation, Mountain View, USA). Maximum
observed concentration, time to Cmax (tmax), AUC from
time 0 to 48 hours post-dose (AUC0–48), AUC0–t,
AUC0–∞, CL, t½, volume of distribution during terminal
elimination phase (Vd) and Vss were determined.
Single oral dose study
Blood concentrations of GSK2239633 were determined by
an internally validated analytical method based on extraction
from a dried blood spot disc by addition of methanol, fol-
lowed by high performance liquid chromatography/tandem
mass spectrometry. The LLQ of the assay was 10 ng/mL
(further details provided as Additional file 1 material). Analy-
sis and derivation of pharmacokinetic parameters were con-
ducted as for the Microdose Intravenous Study.
Safety and tolerability assessments
Microdose and single dose studies
The primary endpoints of the Single Oral Dose Study were
adverse events and clinically relevant changes in safety pa-
rameters. Adverse events were recorded throughout both
studies. For each event, the potential causal relationship
with the study drug was assessed by the investigator. Other
safety assessments in both studies included clinical labora-
tory tests (chemistry, haematology, urinalysis), vital signs,
12-lead electrocardiogram (ECG) and continuous cardiac
telemetry.
Pharmacodynamic analysis
Single oral dose study
Blood samples (9 volumes) were collected into a 3.8%
sodium citrate solution (1 volume) and incubated for
15 minutes at room temperature with saturating concen-
trations of fluorescein isothiocyanate (FITC)-conjugated
mouse anti-human CD4 antibody and non-inactivating
phycoerythrin (PE)-conjugated mouse anti-human CCR4
antibody (BD Biosciences, Oxford, United Kingdom), or
appropriate isotype control antibodies. The samples
were then incubated for 30 minutes at 37°C. For pre-
clinical studies, antagonists or vehicle were added at the
beginning of this incubation. Following this, the blood
cells were incubated for 15 seconds with varying con-
centrations of TARC (PeproTech EC, London, United
Kingdom) before addition of 10 volumes of fluorescence-
activated cell sorting (FACS) lysing solution (BD Bio-
sciences, Oxford, United Kingdom). After 30 minutes, the
blood cell suspension was centrifuged (500 g for 5 minutes)and resuspended in fresh FACS lysing solution for further
10 minutes to ensure complete red blood cell lysis. The
cell suspensions were centrifuged (500 g for 5 minutes)
again and washed twice by resuspending in phosphate
buffered saline (PBS) solution and centrifuging at 500 g
for 5 minutes. After incubating the cell suspensions for
15 minutes with lysophosphatidylcholine (100 μg/mL)
and Alexa fluor 647 phalloidin (0.075 units/mL), the cells
were recovered by centrifugation at 500 g for 5 minutes
and resuspended in PBS. The F-actin content of the CD4+
CCR4+ lymphocytes in each sample was determined on a
FACSCantoII flow cytometer by measuring the mean
Alexa fluor 647 fluorescence intensity of 1,000 cells. This
was expressed as a fraction of the Alexa fluor 647 fluores-
cence intensity of the CCR4– lymphocytes in the same
sample. The fractional occupancy of CCR4 (Ro) was then
estimated by determining the dose-ratio (DR) from the
change in effective concentration giving 50% of the maxi-
mal response (EC50) of the TARC concentration-response
curve before and after dosing with GSK2239633 and using
the formula Ro = (DR – 1)/DR [32].
Statistical analysis
Microdose intravenous study
No formal sample size estimation was performed. As
this was an exploratory study, no formal statistical hy-
potheses for safety, tolerability or pharmacokinetics were
tested.
Single oral dose study
No statistical analysis was done to determine the sample
size. There was no statistical analysis of safety parameters.
Dose proportionality was primarily evaluated based on
Cmax, AUC0–10 and AUC0–t using the power model.
Each parameter was loge-transformed prior to analysis.
Additionally, a mixed model was fitted to the dose-
normalised pharmacokinetic parameters to compare
each dose with the reference dose (GSK2239633
150 mg). The data were loge-transformed prior to analy-
sis and the results were then back-transformed to calcu-
late ratios between the doses. Food effect was assessed
by performing a statistical analysis of Cmax, AUC0–10 and
AUC0–t after loge-transformation of the data. An analysis
of variance (ANOVA) model was fitted along with 90%
confidence intervals (CIs) by a mixed effects model, with
fed/fasted condition as a fixed effect and subject as a
random effect. Using data obtained in the Microdose In-
travenous Study it was possible to make an estimation of
GSK2239633 bioavailability following oral administra-
tion. For that, AUC0–10 was used as a comparison.
For the pharmacodynamic analysis, population esti-
mates of the parameters, such as EC50, were derived
using non-linear mixed effects models in NonMEM
Version 7 (ICON Development Solutions, PA, USA) for
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pharmacodynamic and pharmacokinetic datasets was
conducted to derive mean EC50 estimates pre-dose and
in the presence of GSK2239633 (each subject acted as
their own control as their pre-dose data was compared
with their post-dose data). Although not a direct method
for formal calculation of Ro, this DR was used to give an
estimate of Ro as described above.
Results
Subject disposition and demographics
Microdose intravenous study
Six male subjects were enrolled and completed the study.
The population mean [range] age was 22.7 [20.0–26.0]
years and mean [range] body mass index was 22.1
[19.3–24.6] kg/m2 (Table 1). All subjects were Caucasian.
Single oral dose study
Twenty-four male subjects were enrolled and com-
pleted the study. The population mean [range] age was
37.2 [20.0–65.0] years and mean [range] body mass
index was 24.9 [19.8–29.1] kg/m2 (Table 1). Twenty
(83%) subjects were of Caucasian/European heritage,
one (4%) subject was of Central/South Asian heritage,
one (4%) subject was of South East Asian heritage and
two (8%) subjects were of Arabic/North Africa heritage.
Pharmacokinetics
Microdose intravenous study
Following infusion, the plasma pharmacokinetics of
GSK2239633 and total plasma radioactivity showed a
rapid bi-exponential distribution phase followed by a
slow terminal elimination phase. Terminal elimination
t½ values were 13.5 hours (95% CI: 9.6, 18.8) forTable 1 Summary of subjects demographic characteristics
Demographics Microdose int
Age, years; Mean [range] 22.
Sex; n (%)
Male
Height, cm; Mean [range] 180.0
Weight, kg; Mean [range] 71.
Body mass index, kg/m2; Mean [range] 22.
Ethnicity; n (%)
Hispanic or Latino





Asian-South East Asian heritageGSK2239633 and 31.6 hours (95% CI: 25.4, 39.3) for to-
tal plasma radioactivity (Table 2). Values of AUC for
GSK2239633 were half those obtained for total plasma
radioactivity (AUC0–48: GSK2239633, 4.420 ng.hour/mL;
total plasma radioactivity: 8.840 ng GSK2239633 equiv.
hour/mL). The intrinsic plasma clearance (CL: 21.9 L/hour)
was low to moderate. The observed Vss and Vd values of
119 L (95% CI: 78.4, 182.0) and 424 L (95% CI: 275.0,
654.0), respectively, for GSK2239633 were relatively high
suggesting good distribution of GSK2239633 from the
plasma compartment into tissues. However, a degree of
caution should be taken when interpreting the apparent
high distribution since there was evidence in several sub-
jects of secondary peaks in the concentration-time profiles
although data were sparse. The amount of radioactive
drug-related material recovered in the urine accounted for
approximately 20% of the administered dose.
Single oral dose study
Absorption of GSK2239633 was rapid with Cmax at 1.0–1.5 -
hours across the dose range (Table 3). Values of t½ could
only be calculated for one subject after the 150 mg and the
1200mg (fed) doses, and two subjects after the 1200 mg
(fed) dose as blood concentrations of GSK2239633 were
too erratic and low during the terminal phase for other sub-
jects; for these three subjects, t½ values ranged from 2.9 to
28.3 hours. Generally, both AUC (Additional file 1:
Figure S2A) and Cmax (Additional file 1: Figure S2B) in-
creased with GSK2239633 dose. Results from the power
model analysis indicated a less than dose proportional
increase for AUC0–10 (adjusted mean slope: 0.61; 90%
CI: 0.54, 0.68) and Cmax (adjusted mean slope: 0.76;
90% CI: 0.63, 0.89) as the 90% CIs did not contain
unity (Additional file 1: Table S1). Dose proportionalityravenous study (n = 6) Single oral dose study (n = 24)
7 [20.0–26.0] 37.2 [20.0–65.0]
6 (100%) 24 (100%)
[172.0–187.0] 180.5 [163.0–197.0])
8 [60.1–85.5] 81.0 [65.7–106.0]
1 [19.3–24.6] 24.9 [19.8–29.1]
0 1 (4%)
6 (100%) 23 (96%)




Table 2 Summary of derived plasma GSK2239633 pharmacokinetic parameters in the microdose intravenous study
[14C]-GSK2239633 (n = 6) Total plasma drug-related radioactivity (n = 6)
Parameters Geometric mean (95% CI) Geometric mean (95% CI)*
Cmax (ng/mL) 7.451 (6.114, 9.079) 8.380 (7.503, 9.359)
AUC0–48 (ng.hour/mL) 4.420 (3.515, 5.556) 8.840 (7.538, 10.368)
AUC0–∞ (ng.hour/mL) 4.577 (3.606, 5.810) 11.418 (9.004, 14.480)
t½ (hour)
1 13.5 [8.0–21.2] 31.6 [25.1–43.0]
CL (L/hour) 21.9 (17.2, 27.7) 8.8 (6.9, 11.1)
Vss (L) 119.0 (78.4, 182.0) 249.0 (200.0, 309.0)
Vd (L) 424.0 (275.0, 654.0) 399.0 (322.0, 494.0)
* Concentrations are in ng GSK2239633 equiv/mL and ng GSK2239633 equiv.hour/mL for Cmax and AUC, respectively.
1 Median [range].
CI: confidence interval; Cmax: maximum observed concentration; AUC0–48: area under the concentration-time curve from time 0 to 48 hours post-dose; AUC0–∞:
area under the concentration-time curve from time 0 extrapolated to infinity; t½: half-life; CL: apparent clearance; Vss: volume of distribution at steady state; Vd:
volume of distribution during terminal elimination phase.
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assessed by comparison with the GSK2239633 150 mg
dose level. Mean Cmax and AUC0–t for GSK2239633 fol-
lowing a dose of 1200 mg were 695 ng/mL and 2330 ng.
hour/mL, respectively; these increased to 1410 ng/mL and
6520 ng.hour/mL when the study medication was admin-
istered after a standard FDA high fat/high caloric meal.
The analysis of the food effect for GSK2239633 showed an
increase of 208% in AUC0–10, 180% in AUC0–t and 103%
in Cmax (GSK2239633 1200 mg fed:fasted) in the fed state;
all these differences achieved statistical significance
(Supplemental Table S2). In addition to the increases
observed for Cmax and AUC parameters, absorption of
GSK2239633 was more protracted in the fed condition
with a median tmax of 3.0 hours. GSK2239633 bioavailabil-
ity in the fasted state ranged from 12–14% for the two
lowest doses studied (GSK2239633 150 mg and 300 mg).
For GSK2239633 600 mg and above, estimated bioavai-
lability decreased ranging from 5–9%. In the fed state,Table 3 Summary of derived blood GSK2239633 pharmacokin










534 (430, 663) 923 (695, 1227) 1210 (1055, 1393) 2060
AUC0–t
(ng.hour/mL)




%AUCex (%) 13.7 ND ND
Cmax (ng/mL) 178 (124, 256) 353 (237, 526) 538 (391, 739) 869
tmax (hour)
1 1.5 [1.0–3.0] 1.0 [1.0–3.0] 1.0 [0.5–2.0] 1.
1 Median [range].
AUC0–10: area under the concentration-time curve from time 0 to 10 hours post-dos
from time 0 extrapolated to infinity; ND: not determined; %AUCex: percentage of A




Adverse events were reported by three of the six (50%)
study subjects. The events reported were abdominal dis-
comfort (n = 1), diarrhoea (n = 1), rhinitis (n = 1) and
headache (n = 1); all were mild, transient and had re-
solved at follow-up. The episode of diarrhoea was the
only event judged to be possibly drug-related by the in-
vestigator. There were no clinically significant abnormali-
ties in clinical laboratory results, physical exam, vital
signs, 12-lead ECG parameters or continuous cardiac
telemetry.
Single oral dose study
Nineteen of the 24 (79%) subjects reported adverse










(1552, 2741) 1520 (1175, 1963) 2560 (2026, 3234) 4670 (3783, 5769)
(2242, 4324) 2330 (1499, 3611) 4150 (3121, 5528) 6520 (4264, 9980)
ND ND ND 5180 (3101, 8654)
ND ND ND 9.4 (3.6, 24.8)
(622, 1215) 695 (476, 1016) 1210 (778, 1889) 1410 (1127, 1761)
5 [0.5–3.0] 1.0 [0.5–3.0] 1.0 [0.5–4.0] 3.0 [0.6–4.0]
e; AUC0–t: AUC from time 0 to last measurable concentration; AUC0–∞: AUC
UC0–∞ obtained by extrapolation; Cmax: maximum observed concentration; tmax:

























(n = 8) n (%)
Placebo
(Fed)




Any event 9 (38) 4 (50) 5 (63) 5 (63) 1 (13) 2 (25) 3 (38) 2 (25) 1 (25) 19 (79)
Headache 3 (13) 2 (25) 0 0 1 (13) 1 (13) 1 (13) 0 0 5 (21)
Diarrhoea 2 (8) 0 2 (25) 1 (13) 1 (13) 0 2 (25) 0 0 4 (17)
Rhinitis 1 (4) 1 (13) 0 0 0 0 1 (13) 0 0 2 (8)
Abdominal
pain
0 0 0 0 0 0 1 (13) 0 0 1 (4)
Figure 1 Population fits per dose level for pre-dose (Panel A)
and 1 hour post-dose (Panel B) in the Single Oral Dose Study.
Following single oral dosing of GSK2239633, blood samples were
collected from subjects and stimulated with TARC as described.
Formation of F-actin was determined following staining with Alexa
fluor 647 phalloidin and analysis with a FACSCantoII flow cytometer
by measuring the mean Alexa fluor 647 fluorescence intensity of
1,000 cells. The ratio of F-actin formation in CD4+ CCR4+ and CD4+
CCR4- T-cells was calculated, and the fractional receptor occupancy
of CCR4 (Ro) was then determined by estimating a dose-ratio (DR)
from the change in effective concentration giving 50% of the
maximal response (EC50) of the TARC concentration-response curve
before and after dosing with GSK2239633 and using the formula
Ro = (DR – 1)/DR.
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groups. Forty-six of the 47 (98%) events were graded as
mild or moderate; none was graded as severe. One sub-
ject had a skin mole at screening that was subsequently
excised and found to be a malignant melanoma. This
was reported as an adverse event. The most frequently
reported adverse events were headache and diarrhoea.
Six subjects experienced events judged to be drug-
related by the investigator, the most frequent of which
was diarrhoea reported by three (13%) subjects
(GSK2239633 600 mg: one; GSK2239633 1500 mg: two;
placebo: one). Other events judged to be drug-related
were abdominal pain, chest discomfort, headache, oral
herpes and somnolence (one subject each). All adverse
events resolved by the end of the study except for one
episode of joint injury and one episode of folliculitis. No
trends were detected in changes from baseline for clinical
laboratory test values. The investigator judged there to be
no clinically significant abnormalities in vital sign, 12-lead
ECG parameters or continuous cardiac telemetry.
Pharmacodynamics
Single oral dose study
Dose–response curves for the relative increase in fila-
mentous actin (F-actin) content of CD4+ CCR4+ cells in
response to TARC showed that, although highly variable,
CCR4 inhibition was evident from GSK2239633 150 mg
to 1500 mg (Figure 1). For comparison, the results from
in vitro studies assessing the effect of GSK2239633
(1–10 μM) on TARC-induced increases in F-actin content
of CD4+ CCR4+ T-cells are also presented (Figure 2). At
the GSK2239633 1500 mg dose, the calculated mean level
of CCR4 inhibition equated to a predicted Ro of approxi-
mately 74% at 1 hour after dosing. Predicted Ro levels
decreased over time following the blood pharmacokinetic
profile, which showed an initial rapid peak in blood
GSK2239633 exposure followed by a rapid decline to
much lower levels 4–8 hours post-dose. The Ro estimates
for each dose group at 1 and 4 hours post-dose are pre-
sented in Table 5. Receptor occupancy estimates at 4 hours
post-dose were more variable than those at 1 hour post-
Figure 2 Thymus- and activation-regulated chemokine-induced
increases in F-actin content of CD4+ CCR4+ T-cells in whole
human blood in the absence or presence of GSK2239633 at
1 μM, 3 μM or 10 μM. The data presented are the mean of
independent determinations in three donors. Error bars represent
standard error of the mean.
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was not unexpected given the low blood exposure of
GSK2239633 at the 4 hours post-dose time-point. Blood
from placebo subjects, analysed in the same way and at
the same time-points, did not show any shifts in the re-
sponse curves, which would indicate CCR4 inhibition,
when the post-dose curves were compared with the pre-
dose curves. The placebo data also revealed the inherent
variability in the technique as shown by the approximately
3-fold range in variability for the derived EC50 of TARC
(pre-dose = 0.34 nM; all data = 0.1–0.34 nM).Table 5 Changes in estimated receptor occupancy in the
presence of GSK2239633 in the single oral dose study
GSK22939633
dose
Parameter1,2 Post-dose time point
1 hour 4 hours**
150 mg Ro (95% CI) (%) 63 (NC) 53 (NC)
300 mg Ro (95% CI) (%) 37 (29, 54) 9 (0, 45)
600 mg Ro (95% CI) (%) 72 (71, 75) 14 (13, 14)
900 mg Ro (95% CI) (%) 55 (50, 58) 42 (0, 56)
1200 mg Ro (95% CI) (%) 64 (60, 67) 0 (0, 1)
1500 mg Ro (95% CI) (%) 74 (62, 79) 61 (52, 67)
1 Ro: CCR4 occupancy by GSK2239633 derived from the EC50 ratio (DR) for
each dose group divided by the pre-dose EC50 and converted to an estimate
of CCR4 occupancy (DR-1/DR).
2 95% CI: calculated from the 95% confidence interval (when available) of the
modelled EC50.
** Data generated at 4 hours post-dose with GSK2239633 was highly variable.
Ro: receptor occupancy; CI: confidence interval; NC: not calculated, insufficient
data to generate a measure of variability.Discussion
In the Microdose Intravenous Study, the clearance of
GSK2239633 was low to moderate (approximately 40%
of liver blood flow) with a proportion of the drug
appearing to be well distributed based on the long termi-
nal elimination rate observed, albeit at relatively low
levels and with signs of secondary input. Prior to the
conduct of the Single Oral Dose Study, the systemic bio-
availability of GSK2239633 in humans was predicted to
be, at best, approximately 70%, based on results of the
Microdose Intravenous Study and those obtained in the
pre-clinical studies. This assumed that bioavailability
was limited only by first pass extraction equivalent to
the systemic clearance measured in the Microdose Intra-
venous Study. However, findings in the Single Oral Dose
Study showed that this was an overestimate (see below).
Unchanged GSK2239633 accounted for only 50% of the
total plasma radioactivity following intravenous adminis-
tration with the remaining circulating drug-related mate-
rial comprised of one or more metabolites. A glucuronide
conjugate was identified as a major component of the
metabolised fraction through a pooled plasma analysis.
The blood exposure of GSK2239633 achieved in the
Single Oral Dose Study was substantially lower than that
expected based on the high oral bioavailability obtained
in several pre-clinical species; however, it may be consis-
tent with the physicochemical properties of the mole-
cule, high molecular weight (549) and low solubility
(0.02 mg/mL), and could explain the limited absorption
window observed in humans. Gastric motility and the
presence of food in the stomach could influence the sys-
temic exposure profile of GSK2239633 in the manner
observed in this first in man oral study. The food effect
analysis supports this hypothesis and administration of
GSK2239633 1200 mg in the fed state led to statistically
significant increases in Cmax (103%) and AUC parame-
ters (AUC0–10: 208%; AUC0–t: 180%) compared with the
fasted state. However, other factors, such as solubility,
cannot be excluded. In addition, in the fed state, tmax
was delayed by approximately 1.5 hours compared
with the fasted state. The estimated bioavailability of
GSK2239633 was considerably lower than predicted,
achieving a maximum of only approximately 16% (either
fasted or fed). Therefore, GSK2239633 exposure in the
blood was notably lower than that required to explore a
full pharmacodynamic response, which was reflected in
the low estimated Ro observed for the actin polymerisa-
tion pharmacodynamic endpoint.
In these early studies, GSK2239633 had a satisfactory
safety and tolerability profile in healthy subjects. No dose-
limiting toxicity or maximum tolerated dose was identi-
fied. There was no relationship in the frequency or
severity of adverse events with increasing doses of
GSK2239633. The anti-CCR4 antibody, mogamulizumab,
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population for this was patients with relapsed CCR4+
adult T-cell lymphomas and other peripheral T-cell
lymphomas [27]. Mogamulizumab has thus far been
shown to be well-tolerated in that study population and
none of the adverse events reported were specific to inhi-
bition of CCR4 [27].
Pharmacodynamic analysis in the Single Oral Dose
Study revealed that GSK2239633 inhibited TARC-induced
increases in the F-actin content of CCR4+ T cells in
human whole blood. Although, even at the highest dose
(1500 mg), the magnitude of inhibition was low (the po-
tency of TARC decreased only 4-fold indicating that the
mean estimated receptor occupancy was 74% at 1 hour
post-dose) and relatively short-acting (reflecting the rapid
reduction of drug concentration and inhibition in the
blood at 4 hours post-dose). GSK2239633 failed to achieve
the minimum target level of CCR4 inhibition in the blood
(≥90% at peak and 50% at trough), and there was no indi-
cation of an extended duration of action (prolonged phar-
macodynamic response in the absence of pharmacokinetic
exposure) in whole blood ex vivo. In this study, we were
unable to obtain systemic exposure of GSK2239633 high
enough to inhibit CCR4 by more than 80% as measured in
the whole blood CCR4 pharmacodynamic assay. This
would substantially limit the degree to which we would be
able to assess the blockade of CCR4 for clinical benefit in
further studies.
CC-Chemokine receptor 4 is potentially involved in
the pathogenesis of allergic diseases due to its involve-
ment in the pathways leading to the recruitment of Th2
cells to the sites of allergen exposure [22,33]. A number
of small-molecule CCR4 antagonists have shown pro-
mising results in various animal models of inflammation,
such as reduction in ovalbumin-induced ear swelling in
mice [34], inhibition of ovalbumin-induced airway in-
flammation in guinea pigs [35] and a reduction in the re-
cruitment of Th2 cells to the lungs in a mouse model of
ovalbumin-induced airway allergy [36]. However, no
small molecules have progressed to clinical studies thus
far [2,26], which may be due, in part, to poor oral expo-
sure noted in pre-clinical animal models with some of
the small molecules reported. A further general chal-
lenge with chemokines often speculated upon is the po-
tential for redundancy within the chemokine system and
alteration of function during evolution [2,37]. Results
from some studies [38-40] indicate that chemokine re-
ceptors are also a good target for adjuvant discovery, in
particular CCR4, as this receptor is expressed by regula-
tory T cells, a subset of T cells which normally functions
in the down-regulation of immune responses induced by
dendritic cells [41]. One of these studies identified CCR4
antagonists acting as adjuvants for both cellular and hu-
moral immune responses.Conclusions
Results obtained from these early studies conducted in
healthy subjects, indicate that GSK2239633 was generally
safe and well tolerated. GSK2239633 exhibited low and
saturable systemic exposures and at the highest dose
level of 1500 mg the peak inhibition of CCR4 by
GSK2239633 in the blood (at 1 hour) was below 80% and
less than 50% by 4 hours post-dose. Based on the low
exposure and target engagement in blood, this molecule
is not considered suitable for further development for an
asthma indication at this time.
Additional file
Additional file 1: Safety, tolerability, pharmacokinetics and
pharmacodynamics of GSK2239633, a CC-chemokine receptor 4
antagonist, in healthy male subjects. Detailed information of the
pharmacokinetic assays, 2 Tables, 2 Figures and figure legends.
Abbreviations
ANOVA: Analysis of variance; AUC0–48: Area under the concentration-time
curve from time 0 to 48 hours post-dose; AUC0–t: AUC from time 0 to last
measurable concentration; AUC0–∞: AUC from time 0 extrapolated to infinity;
CCR4: CC-chemokine receptor 4; CI: Confidence Intervals; CL: Apparent
clearance; Cmax: Maximum observed concentration; DR: Dose-Ratio;
EC50: Effective concentration giving 50% of the maximal response;
FACS: Fluorescence-activated cell sorting; FDA: United states food and drug
administration; FITC: Fluorescein isothiocyanate; LLQ: Lower limit of
quantification; MDC: Monocyte-derived chemokine; PBS: Phosphate buffered
saline; PE: Phycoerythrin; Ro: Fractional occupancy; TARC: Thymus- and
activation-regulated chemokine; t½: Terminal half-life; tmax: Time to Cmax;
Th2: Type 2 T helper; Vd: Volume of distribution during terminal elimination
phase; Vss: Volume of distribution at steady state.
Competing interests
Anthony Cahn, Simon Hodgson, Robert Wilson, Jonathan Robertson, Joanna
Watson, Misba Beerahee, Steve C. Hughes, Graeme Young, Rebecca Graves,
David Hall and Roberto Solari are GlaxoSmithKline employees. Sjoerd van
Marle has no competing interests.
Authors’ contributions
AC, RW, JR and MB participated in the conception and design of the study,
and in the analysis and interpretation of the data. JW and SCH participated
in the conception and design of the study, and in the acquisition, analysis
and interpretation of the data. SH, DH and SVM took part in the acquisition,
analysis and interpretation of the data. GY, RG and RS contributed in the
analysis and interpretation of the data. All authors have made critical
revisions of draft versions of the manuscript and approved the final
manuscript.
Acknowledgements
The authors would like to thank the subjects and staff who participated in
the studies. All listed authors meet the criteria for authorship set forth by the
International Committee for Medical Journal Editors. Medical writing and
editorial support to prepare the manuscript were provided by Dr Justin Cook
and Dr Severina Moreira of Niche Science and Technology Ltd (Richmond-
upon-Thames, United Kingdom), who were paid by GlaxoSmithKline for
these services. These studies (NCT01086462 and NCT01371812) were funded
by GlaxoSmithKline.
Author details
1Medicines Discovery and Development, Gunnels Wood Road, Stevenage
Herts SG1 2NY, UK. 2GlaxoSmithKline, Stockley Park West, Uxbridge,
Middlesex UB11 1BT, UK. 3GlaxoSmithKline, Park Road, Ware SG12 0DP, UK.
4PRA International, Stationsweg 163, Zuidlaren 9741 GP, the Netherlands.
Cahn et al. BMC Pharmacology and Toxicology 2013, 14:14 Page 10 of 11
http://www.biomedcentral.com/bmcpharmacoltoxicol/2050-6511/14/1/14Received: 27 August 2012 Accepted: 26 February 2013
Published: 28 February 2013References
1. Finiasz M, Otero C, Bezrodnik L, Fink S: The role of cytokines in atopic
asthma. Curr Med Chem 2011, 18:1476–1487.
2. Pease JE: Targeting Chemokine receptors in allergic disease.
Biochem J 2011, 434:11–24.
3. Azzawi M, Bradley B, Jeffery PK, Frew AJ, Wardlaw AJ, Knowles G, Assoufi B,
Collins JV, Durham S, Kay AB: Identification of activated T lymphocytes
and eosinophils in bronchial biopsies in stable atopic asthma.
Am Rev Respir Dis 1990, 142:1407–1413.
4. Fanta CH: Asthma. N Engl J Med 2009, 360:1002–1014.
5. Hamid Q, Tulic M: Immunobiology of asthma. Annu Rev Physiol 2009,
71:489–507.
6. Long AA: Immunomodulators in the treatment of asthma.
Allergy Asthma Proc 2009, 30:109–119.
7. Minai-Fleminger Y, Levi-Schaffer F: Mast cells and eosinophils: the two key
effector cells in allergic inflammation. Inflamm Res 2009, 58:631–638.
8. Vestergaard C, Yoneyama H, Murai M, Nakamura K, Tamaki K, Terashima Y,
Imai T, Yoshie O, Irimura T, Mizutani H, Matsushima K: Overproduction of
Th2-specific Chemokines in NC/Nga mice exhibiting atopic dermatitis-
like lesions. J Clin Invest 1999, 104:1097–1157.
9. Vestergaard C, Bang K, Gesser B, Yoneyama H, Matsushima K, Larsen CG: A
Th2 Chemokine, TARC, produced by keratinocytes may recruit CLA +
CCR4+ lymphocytes into lesional atopic dermatitis skin.
J Invest Dermatol 2000, 115:640–646.
10. Sekiya T, Miyamasu M, Imanishi M, Yamada H, Nakajima T, Yamaguchi M,
Fujisawa T, Pawankar R, Sano Y, Ohta K, Ishii A, Morita Y, Yamamoto K,
Matsushima K, Yoshie O, Hirai K: Inducible expression of a Th2-type CC
Chemokine thymus- and activation-regulated Chemokine by human
bronchial epithelial cells. J Immunol 2000, 165:2205–2213.
11. Zheng X, Nakamura K, Furukawa H, Nishibu A, Takahashi M, Tojo M, Kaneko
F, Kakinuma T, Tamaki K: Demonstration of TARC and CCR4 mRNA
expression and distribution using in situ RT-PCR in the lesional skin of
atopic dermatitis. J Dermatol 2003, 30:26–32.
12. Liu YJ: Thymic stromal lymphopoietin: master switch for allergic
inflammation. J Exp Med 2006, 203:269–273.
13. Imai T, Baba M, Nishimura M, Kakizaki M, Takagi S, Yoshie O: The T cell-
directed CC Chemokine TARC is a highly specific biological ligand for CC
Chemokine receptor 4. J Biol Chem 1997, 272:15036–15042.
14. Imai T, Chantry D, Raport CJ, Wood CL, Nishimura M, Godiska R, Yoshie O,
Gray PW: Macrophage-derived Chemokine is a functional ligand for the
CC Chemokine receptor 4. J Biol Chem 1998, 273:1764–1768.
15. Imai T, Nagira M, Takagi S, Kakizaki M, Nishimura M, Wang J, Gray PW,
Matsushima K, Yoshie O: Selective recruitment of CCR4-bearing Th2 cells
toward antigen-presenting cells by the CC Chemokines thymus and
activation-regulated Chemokine and macrophage-derived Chemokine.
Int Immunol 1999, 11:81–88.
16. Sallusto F, Lenig D, Mackay CR, Lanzavecchia A: Flexible programs of
Chemokine receptor expression on human polarized T helper 1 and 2
lymphocytes. J Exp Med 1998, 187:875–883.
17. D’Ambrosio D, Iellem A, Bonecchi R, Mazzeo D, Sozzani S, Mantovani A,
Sinigaglia F: Selective up-regulation of Chemokine receptors CCR4 and
CCR8 upon activation of polarized human type 2 Th cells. J Immunol
1998, 161:5111–5115.
18. Bochner BS, Hudson SA, Xiao HQ, Liu MC: Release of both CCR4-active and
CXCR3-active Chemokines during human allergic pulmonary late-phase
reactions. J Allergy Clin Immunol 2003, 112:930–934.
19. Pilette C, Francis JN, Till SJ, Durham SR: CCR4 Ligands are up-regulated in
the airways of atopic asthmatics after segmental allergen challenge.
Eur Respir J 2004, 23:876–884.
20. Panina-Bordignon P, Papi A, Mariani M, Di Lucia P, Casoni G, Bellettato C,
Buonsanti C, Miotto D, Mapp C, Villa A, Arrigoni G, Fabbri LM, Sinigaglia F:
The C-C Chemokine receptors CCR4 and CCR8 identify airway T cells of
allergen-challenged atopic asthmatics. J Clin Invest 2001, 107:1357–1364.
21. Morgan AJ, Symon FA, Berry MA, Pavord ID, Corrigan CJ, Wardlaw AJ: IL-4-
expressing bronchoalveolar T cells from asthmatic and healthy subjectspreferentially express CCR 3 and CCR 4. J Allergy Clin Immunol 2005,
116:594–600.
22. Vijayanand P, Durkin K, Hartmann G, Morjaria J, Seumois G, Staples KJ, Hall
D, Bessant C, Bartholomew M, Howarth PH, Friedmann PS, Djukanovic R:
Chemokine receptor 4 plays a key role in T cell recruitment into the
airways of asthmatic patients. J Immunol 2010, 184:4568–4574.
23. Barnes PJ: Immunology of asthma and chronic obstructive pulmonary
disease. Nat Rev Immunol 2008, 8:183–192.
24. Barnes PJ: The cytokine network in asthma and chronic obstructive
pulmonary disease. J Clin Invest 2008, 118:3546–3556.
25. Donnelly LE, Barnes PJ: Chemokine receptors as therapeutic targets in
chronic obstructive pulmonary disease. Trends Pharmacol Sci 2006,
27:546–553.
26. Hall D, Ford A, Hodgson S: Therapeutic potential of CCR4 antagonists.
In New drugs and targets for asthma and COPD. Volume 39. Karger:
Prog Respir Res Basel; 2010:161–165.
27. Yamamoto K, Utsunomiya A, Tobinai K, Tsukasaki K, Uike N, Uozumi K,
Yamaguchi K, Yamada Y, Hanada S, Tamura K, Nakamura S, Inagaki H,
Ohshima K, Kiyoi H, Ishida T, Matsushima K, Akinaga S, Ogura M, Tomonaga
M, Ueda R: Phase I study of KW-0761, a defucosylated humanized anti-
CCR4 antibody, in relapsed patients with adult T-cell leukemia-
lymphoma and peripheral T-cell lymphoma. J Clin Oncol 2010,
28:1591–1598.
28. Procopiou PA, Ford AJ, Graves RH, Hall DA, Hodgson ST, Lacroix YM,
Needham D, Slack RJ: Lead optimisation of the N1 substituent of a novel
series of indazole arylsulfonamides as CCR4 antagonists and
identification of a candidate for clinical investigation. Bioorg Med Chem
Lett 2012, 22:2730–2733.




30. ICH M3 (R2) - guideline on nonclinical safety studies for the conduct of human
clinical trials and marketing authorization for pharmaceuticals. http://www.
ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/
WC500002941.pdf.
31. World Medical Association: Declaration of Helsinki - ethical principles for
medical research involving human subjects. http://www.wma.net/en/
30publications/10policies/b3.
32. Paton WDM: A theory of drug action based on the rate of drug-receptor
combination. Proc R Soc Lond B 1961, 154:21–69.
33. Banfield G, Watanabe H, Scadding G, Jacobson MR, Till SJ, Hall DA, Robinson DS,
Lloyd CM, Nouri-Aria KT, Durham SR: CC Chemokine receptor 4 (CCR4) in
human allergen-induced late nasal responses. Allergy 2010,
65:1126–1133.
34. Nakagami Y, Kawashima K, Yonekubo K, Etori M, Jojima T, Miyazaki S,
Sawamura R, Hirahara K, Nara F, Yamashita M: Novel CC Chemokine
receptor 4 antagonist RS-1154 inhibits ovalbumin-induced ear swelling
in mice. Eur J Pharmacol 2009, 624:38–44.
35. Nakagami Y, Kawase Y, Yonekubo K, Nosaka E, Etori M, Takahashi S, Takagi
N, Fukuda T, Kuribayashi T, Nara F, Yamashita M: RS-1748, a novel CC
Chemokine receptor 4 antagonist, inhibits ovalbumin-induced airway
inflammation in guinea pigs. Biol Pharm Bull 2010, 33:1067–1079.
36. Sato T, Komai M, Iwase M, Kobayashi K, Tahara H, Ohshima E, Arai H, Miki I:
Inhibitory effect of the new orally active CCR4 antagonist K327 on
CCR4 + CD4+ T cell migration into the lung of mice with ovalbumin-
induced lung allergic inflammation. Pharmacology 2009, 84:171–182.
37. Catley MC, Coote J, Bari M, Tomlinson KL: Monoclonal antibodies for the
treatment of asthma. Pharmacol Ther 2011, 132:333–351.
38. Bayry J, Tchilian EZ, Davies MN, Forbes EK, Draper SJ, Kaveri SV, Hill AV,
Kazatchkine MD, Beverley PC, Flower DR, Tough DF: In silico identified
CCR4 antagonists target regulatory T cells and exert adjuvant activity in
vaccination. Proc Natl Acad Sci USA 2008, 105:10221–10226.
39. Davies MN, Bayry J, Tchilian EZ, Vani J, Shaila MS, Forbes EK, Draper SJ,
Beverley PC, Tough DF, Flower DR: Toward the discovery of vaccine
adjuvants: coupling in silico screening and in vitro analysis of
antagonist binding to human and mouse CCR4 receptors. PLoS One
2009, 4:e8084.
40. Pere H, Montier Y, Bayry J, Quintin-Colonna F, Merillon N, Dransart E,
Cahn et al. BMC Pharmacology and Toxicology 2013, 14:14 Page 11 of 11
http://www.biomedcentral.com/bmcpharmacoltoxicol/2050-6511/14/1/14Badoual C, Gey A, Ravel P, Marcheteau E, Batteux F, Sandoval F, Adotevi O,
Chiu C, Garcia S, Tanchot C, Lone YC, Ferreira LC, Nelson BH, Hanahan D,
Fridman WH, Johannes L, Tartour E: A CCR4 antagonist combined with
vaccines induces antigen-specific CD8+ T cells and tumor immunity
against self antigens. Blood 2011, 118:4853–4862.
41. Miyara M, Sakaguchi S: Natural regulatory T cells: mechanisms of
suppression. Trends Mol Med 2007, 13:108–116.
doi:10.1186/2050-6511-14-14
Cite this article as: Cahn et al.: Safety, tolerability, pharmacokinetics
and pharmacodynamics of GSK2239633, a
CC-chemokine receptor 4 antagonist, in healthy male subjects: results
from an open-label and from a randomised study. BMC Pharmacology
and Toxicology 2013 14:14.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
